Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19

Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Giuseppe, Giotta, Massimo, Perelli, Serena, De Vita, Giuseppina, Bartolomeo, Nicola, Buccoliero, Giovanni Battista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695104/
https://www.ncbi.nlm.nih.gov/pubmed/36423123
http://dx.doi.org/10.3390/v14112514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695104/
https://www.ncbi.nlm.nih.gov/pubmed/36423123
http://dx.doi.org/10.3390/v14112514

Ejemplares similares